ArticleCureus2026
Early Experience With Defensive Antibacterial Coating (DAC®) Hydrogel in High-Risk Orthopaedic Implant Surgery.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeriprosthetic joint infections (PJIs) after hip and knee arthroplasty and osteosynthesis-associated infections (OAIs) after fracture fixation remain major clinical and economic burdens. High-risk patients with advanced age, multiple comorbidities, and socioeconomic deprivation are particularly vulnerable. Defensive Antibacterial Coating (DAC®) hydrogel (Novagenit S.r.l., Mezzolombardo, Italy) is a fully resorbable hyaluronic acid/poly-D,L-lactide coating that reduces early bacterial adhesion and can act as a carrier for local antibiotic delivery.
methodsA retrospective cohort study was conducted including patients who underwent orthopaedic arthroplasty or osteosynthesis procedures with intraoperative DAC® application between April 2022 and October 2023. Patients were selected based on clinical factors associated with an increased risk of postoperative infection, including advanced age, multiple comorbidities, the nature of the planned orthopaedic procedure, and consultant surgeon judgement. Demographic, biochemical, and deprivation (Welsh Index of Multiple Deprivation (WIMD)) data were collected. Operative time and perioperative variables were recorded where available. Patients were reviewed clinically and radiographically at six weeks and six months. Results: Twenty-one patients received DAC®. The mean age was 72.5±15.04 years, American Society of Anesthesiologists (ASA) 2.57±0.74, Charlson Comorbidity Index 5.76±2.34, and deprivation score 6.89±2.37. Procedures included the hip/femur (n=9), knee (n=2), foot and ankle (n=6), and shoulder (n=4). Procedures were further analysed in two groups: arthroplasty (n=6) and osteosynthesis (n=15). The mean operative time was 146.80±32.91 minutes (range: 81-193 minutes). No postoperative implant-related infections were identified during the six-week and six-month follow-up period. Conclusion: In this real-world high-risk cohort, no postoperative implant-related infections were identified following intraoperative DAC® hydrogel use. Larger controlled studies are required to confirm efficacy and cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.